Share this page
Complex function designed by nature
)
albunorm®,
a human albumin solution1
Albumin is a multifunctional protein with a stable, flexible, complex and modifiable structure. Its biological actions are linked to distribution and molecular concentration, regulating intravascular volume2 and acting in the transport of molecules. It also has antioxidant and immunomodulatory properties3,4, as well as a possible role as an endothelial stabiliser.
The haemodynamics of albumin are better maintained compared to crystalloids2
It has antioxidant and
anti-inflammatory properties3,4
Less positive perioperative fluid balance5
albunorm® is indicated for Restoration and maintenance of circulating blood volume 1
where volume deficiency has been demonstrated, and use of a colloid is appropriate.
In haemorrhagic shock, shock due to loss of plasma and other situations accompanied by shock.1
As replacement therapy in patients with severe albumin deficiency, including the one developed before, during or after surgery.1
The product formulation is suitable for administration to patients undergoing dialysis and to premature infants.1
Evaluated in all relevant clinical settings
The colloid of choice
in critically ill patients
Effective volume expansion6
(up to 300% in the case of albumin 20%)
Duration of effect of 12 to 24 hours7
Lower rate of allergic reactions compared to gelatines8
References
octalbin® - Bula do Profissional da Saúde. Bulário eletrônico. Agência Nacional de Vigilância Sanitária. Bula aprovada em 10 de junho de 2024. [Anvisa]
Sedrakyan A, Gondek K, Paltiel D, Elefteriades JA. Volume expansion with albumin decreases mortality after coronary artery bypass graft surgery. Chest. 2003 Jun;123(6):1853-7. doi: 10.1378/chest.123.6.1853. PMID: 12796160. [PubMed]
Evans TW. Review article: albumin as a drug--biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 2002 Dec;16 Suppl 5:6-11. doi: 10.1046/j.1365-2036.16.s5.2.x. PMID: 12423448. [PubMed]
Horstick G, Lauterbach M, Kempf T, Bhakdi S, Heimann A, Horstick M, Meyer J, Kempski O. Early albumin infusion improves global and local hemodynamics and reduces inflammatory response in hemorrhagic shock. Crit Care Med. 2002 Apr;30(4):851-5. doi: 10.1097/00003246-200204000-00023. PMID: 11940758. [PubMed]
Skhirtladze K, Base EM, Lassnigg A, Kaider A, Linke S, Dworschak M, Hiesmayr MJ. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth. 2014 Feb;112(2):255-64. doi: 10.1093/bja/aet348. Epub 2013 Oct 29. PMID: 24169821. [PubMed]
Jacob M, Chappell D, Conzen P, Wilkes MM, Becker BF, Rehm M. Small-volume resuscitation with hyperoncotic albumin: a systematic review of randomized clinical trials. Crit Care. 2008;12(2):R34. doi: 10.1186/cc6812. Epub 2008 Mar 4. PMID: 18318896; PMCID: PMC2447554. [PubMed]
Kruer RM, Ensor CR. Colloids in the intensive care unit. Am J Health Syst Pharm. 2012 Oct 1;69(19):1635-42. doi: 10.2146/ajhp110414. PMID: 22997116. [PubMed]
Laxenaire MC, Charpentier C, Feldman L. Réactions anaphylactoïdes aux substituts colloïdaux du plasma: incidence, facteurs de risque, mécanismes. Enquête prospective multicentrique française. Groupe Français d'Etude de la Tolérance des Substituts Plasmatiques [Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study]. Ann Fr Anesth Reanim. 1994;13(3):301-10. French. doi: 10.1016/s0750-7658(94)80038-3. PMID: 7992937. [PubMed]
